Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

Pioneering therapeutic antibody optimization, Therapeutics utilizes advanced technologies to improve drug development and clinical translation.

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Strong growth was reported with the breast cancer medicines, Perjeta and Kadcyla, and lung cancer medicines, Tecentriq and Alecensa. Directors said that cancer medicines Avastin, Herceptin ...

Asthma drug Xolair generated sales of CHF 2.5 billion, up 16% year over year. Breast cancer drug Kadcyla generated sales of CHF 2 billion, up 7% during the said time frame. Breast cancer drug ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...

Antibody–drug conjugates (ADCs) represent a breakthrough in cancer therapy, combining the precision of monoclonal antibodies with powerful chemotherapeutic drugs. While ADC development is accelerating ...

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Since the enactment of the Biologics Price ...